trial

Pharmacovigilance in Gerontopsychiatric Patients

NCTId NCT02374567

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase 3 · Terminated

Enrollment 407 (actual)

Design & status

Phase

Phase 3

Status

Terminated

Enrollment

407 (actual)

Study type

Interventional

Allocation

Model

Single Group

Masking

None

Start

2015-01

Primary completion

2017-06-28

Eligibility

ALL · 65 Years

Interventions & indications

Drugs

Phenobarbital Phenytoin Carbamazepine Oxcarbazepine Valproic Acid lamotrigine topiramate Gabapentin Levetiracetam Pregabalin Lacosamide Clonazepam Biperiden Levomepromazine Fluphenazine Perphenazine Perazine Thioridazine Haloperidol Melperone Pipamperone bromperidol Benperidol Sertindole Ziprasidone Flupentixol Chlorprothixene Zuclopenthixol Fluspirilene Pimozide Clozapine Olanzapine Quetiapine Sulpiride Tiapride Amisulpride Prothipendyl Risperidone Aripiprazole Paliperidone Diazepam Oxazepam Lorazepam Bromazepam Clobazam Alprazolam Hydroxyzine Buspirone Chloral Hydrate Flurazepam nitrazepam Triazolam Lormetazepam Temazepam Midazolam Brotizolam Zopiclone Zolpidem Zaleplon Melatonin Clomethiazole Diphenhydramine Promethazine Imipramine Clomipramine Opipramol Trimipramine Amitriptyline Nortriptyline Doxepin Maprotiline Amitriptyline oxide fluoxetine Citalopram Paroxetine Sertraline Fluvoxamine escitalopram tranylcypromine Moclobemide Mianserin Trazodone mirtazapine Bupropion Venlafaxine Reboxetine Duloxetine agomelatine Pyritinol Piracetam Donepezil Rivastigmine Galantamine Memantine Nicergoline Acamprosate Lithium

Indications

Dementia Dementia Psychosomatic Disorders Depression Schizophrenia Schizophrenia Psychophysiologic Disorders Anxiety Disorders Depression Anxiety Disorders

Investigators

Helge Frieling, Prof., MDPrincipal Investigator

Sites

5 total

Augsburg, GermanyBerlin, GermanyHanover, GermanyLubin, GermanyTeupitz, Germany

Linked catalysts

Pharmacovigilance in Gerontopsychiatric Patients — primary completion2017-06-28

Facts & assertions

4 sourced

Enrollment

407

Phase

PHASE3

Primary Completion Date

2017-06-28

Status

TERMINATED

relationships

The graph out of here

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

drug

lead_sponsor

Hannover Medical School

company

indication

Dementia

indication

Dementia

indication

Psychosomatic Disorders

indication

investigator

Helge Frieling, Prof., MD

person